<DOC>
	<DOCNO>NCT02304419</DOCNO>
	<brief_summary>The main purpose study learn study drug call galunisertib affect immune system participant cancer . The study treatment expect last six month participant , include screen follow-up .</brief_summary>
	<brief_title>A Study Galunisertib Immune System Participants With Cancer</brief_title>
	<detailed_description />
	<criteria>Have confirm diagnosis advance , refractory solid tumor tumor progression treatment intolerance least 1 prior therapy . Have measurable disease amenable radiographic ultrasoundguided biopsy may biopsied office without radiologic guidance . Have performance status ≤2 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue diseasemodifying therapy primary cancer 28 day prior initiation study treatment . Hepatic : bilirubin ≤1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) ≤3.0 time ULN . For participant tumor involvement liver , AST ALT equal ≤5.0 time ULN acceptable . Alkaline phosphatase ≤5.0 time ULN participant tumor involvement bone acceptable . Have adequate renal function , define serum creatinine level ≤2.0 ULN calculate creatinine clearance &gt; 45 mL/min . Male female participant reproductive potential must use approved contraceptive method , appropriate ( example , intrauterine device , birth control pill , barrier device ) 6 month discontinuation study treatment . Women childbearing potential must negative betahuman chorionic gonadotropin pregnancy test document within 7 day prior treatment . Have give write informed consent prior studyspecific procedure . Are willing able comply study procedure instruction , include completion diary . Must receive least 1 prior approve immunotherapy chemotherapy ; however , within 28 day initial dose study drug . May receive prior radiotherapy malignancy . May receive treatment investigational product . Are enrolled type medical research judge scientifically medically compatible study within 28 day initial dose study drug . Have moderate severe cardiac disease : Have presence cardiac disease , include myocardial infarction within 6 month prior study entry , unstable angina pectoris , New York Heart Association Class III/IV congestive heart failure , uncontrolled hypertension . Have document major electrocardiogram ( ECG ) abnormality ( respond medical treatment ) investigator 's discretion ( example , symptomatic sustain atrial ventricular arrhythmia , second thirddegree atrioventricular block , complete bundle branch block , ventricular hypertrophy , recent myocardial infarction ) . Have major abnormality document echocardiography ( ECHO ) Doppler ( example , moderate severe heart valve function defect and/or leave ventricular ejection fraction &lt; 50 % , evaluation base institutional low limit normal ) . Have predispose condition consistent development aneurysm ascend aorta aortic stress ( example , family history aneurysm , MarfanSyndrome , bicuspid aortic valve , evidence damage large vessel heart document compute tomography ( CT ) scan contrast ) . Are woman pregnant lactating . Have serious concomitant systemic disorder ( example , active infection include human immunodeficiency virus [ HIV ] , hepatitis C virus [ HCV ] , hepatitis B virus [ HBV ] [ ie , positive hepatitis B surface antigen [ +HBsAg ] ] ) , autoimmune disease . Have second primary malignancy history time frame prior malignancy . Are unwilling unable participate , tissue adequate participation biomarker analyse study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>